top of page

The Zeglis Laboratory is supported by the following awards from the National Institutes of Health:

Current Funding

 

  • NIH/NCI 1R44CA295134 (9/18/25-8/31/29; a collaboration between the Zeglis Laboratory and Serva Energy) Providing GMP Grade Terbium-161 as a Therapeutic Option for U.S. Academic Institutions​

​

  • NIH/NCI 1R21CA309945 (5/13/26-4/30/28; a collaboration between the Zeglis Laboratory and Dr. Filemon Dela Cruz at Memorial Sloan Kettering Cancer Center) The Development of Radiotherapeutic Paradigms for Desmoplastic Small Round Cell Tumor

​

  • MacMillan Foundation (11/01/25-10/31/28) The Development of Radiotheranostics Paradigms for Endometrial Cancer

​

  • NIH/NCI 1R01AI175417 (10/01/23-9/30/28; a collaboration between the Zeglis Laboratory and the Gomes-Solecki Laboratory at the University of Tennessee Health Science Campus) ImmunoPET Probes for the Imaging of Lyme Disease

 

  • NIH/NCI 1R01CA281801 (7/01/23-6/30/28; a collaboration between the Zeglis Laboratory and the Lampe Laboratory at the Fred Hutchinson Cancer Research Center) Autoantibodies to Tumor-Derived Neoepitopes as Biomarkers and ImmunoPET Agents for the Early Detection of Small Cell Lung Cancer​​​​

Expired Funding

 

  • NIH/NCI R01CA244327 (7/01/20-6/30/25; a collaboration between the Zeglis Laboratory and the Bournazos Laboratory at Rockefeller University) Novel Transgenic Mouse Models Addressing Outstanding Translational Barriers in Antibody-Based Therapeutics

​

  • NIH/NCI 1R21CA280595 (10/01/23-9/30/25; a collaboration between the Zeglis Laboratory and the Humm Laboratory at Memorial Sloan Kettering Cancer Center) Targeting DNA Mismatches for Auger Electron Radiotherapy

​

  • NIH/NCI U01CA221046 (4/01/18-3/31/23; a collaboration between the Zeglis Laboratory and the Lewis Laboratory at Memorial Sloan Kettering Cancer Center) Pretargeted Clinical Imaging of CA19.9 in Pancreatic Cancer

 

  • NIH/NCI R01CA20416 (4/01/16-3/31/21; a collaboration between the Zeglis Laboratory and the Lewis Laboratory at Memorial Sloan Kettering Cancer Center) The Clinical PET Imaging of Metastatic Breast Cancer with Site-Specifically Labeled 89Zr-Trastuzumab

 

  • NIH/NCI U01CA221046 (7/09/19-6/30/24; a collaboration between the Zeglis Laboratory and the Zheng Laboratory at Hunter College) Novel Reagents for Rapid and Stable Thiol-Based Bioconjugations

 

  • NIH/NIBIB R21EB030275 (6/01/20-5/31/22; a collaboration between the Zeglis Laboratory and the Qiu Laboratory at Hunter College) A PET Radiotracer for the Diagnostic and Theranostic Imaging of Lyme Disease

 

​The Zeglis Laboratory is also grateful to the NIH F31 program for a training award to Camilla Grimaldi and the NanoBioNYC Program (NSF) for a training award to Kiarra Furey

​

tenor.gif
bottom of page